002603 Stock Overview
Shijiazhuang Yiling Pharmaceutical Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥16.53 |
| 52 Week High | CN¥24.47 |
| 52 Week Low | CN¥14.37 |
| Beta | 0.19 |
| 1 Month Change | -5.70% |
| 3 Month Change | 12.76% |
| 1 Year Change | -28.57% |
| 3 Year Change | -12.45% |
| 5 Year Change | 104.98% |
| Change since IPO | 34.67% |
Recent News & Updates
Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Business Is Trailing The Industry But Its Shares Aren't
Nov 26
Shijiazhuang Yiling Pharmaceutical's (SZSE:002603) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Nov 04Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Using Too Much Debt?
Sep 25Recent updates
Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Business Is Trailing The Industry But Its Shares Aren't
Nov 26Shijiazhuang Yiling Pharmaceutical's (SZSE:002603) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Nov 04Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Using Too Much Debt?
Sep 25Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Subdued P/S Might Signal An Opportunity
Aug 07Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Has Announced That Its Dividend Will Be Reduced To CN¥0.30
Jul 15Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) A Risky Investment?
May 26Weak Statutory Earnings May Not Tell The Whole Story For Shijiazhuang Yiling Pharmaceutical (SZSE:002603)
May 05Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) Analysts Just Cut Their EPS Forecasts Substantially
May 02Should You Be Adding Shijiazhuang Yiling Pharmaceutical (SZSE:002603) To Your Watchlist Today?
Mar 01Shareholder Returns
| 002603 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -4.3% | -1.9% | -1.2% |
| 1Y | -28.6% | -1.8% | 11.8% |
Return vs Industry: 002603 underperformed the CN Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: 002603 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 002603 volatility | |
|---|---|
| 002603 Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 002603 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002603's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 13,958 | Xiang Jun Wu | www.yiling.cn |
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine primarily in China. It offers drugs for respiratory health, cardiovascular disease, diabetes mellitus, oncology, urologic disease, sleep-improving, and anti-aging. The company also provides dietary supplements, health food and drinks, disinfection products, and personal protective equipment, as well as formula granules.
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Fundamentals Summary
| 002603 fundamental statistics | |
|---|---|
| Market cap | CN¥27.62b |
| Earnings (TTM) | CN¥148.47m |
| Revenue (TTM) | CN¥8.11b |
186.0x
P/E Ratio3.4x
P/S RatioIs 002603 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002603 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.11b |
| Cost of Revenue | CN¥4.06b |
| Gross Profit | CN¥4.05b |
| Other Expenses | CN¥3.90b |
| Earnings | CN¥148.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.089 |
| Gross Margin | 49.96% |
| Net Profit Margin | 1.83% |
| Debt/Equity Ratio | 11.1% |
How did 002603 perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield338%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 06:14 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shijiazhuang Yiling Pharmaceutical Co., Ltd. is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Weiying Tu | China International Capital Corporation Limited |
| Diandian Li | China Merchants Securities Co. Ltd. |